However, nirmatrelvir requires pharmacokinetic boosting with the cytochrome P450 3A4 inhibitor ritonavir, which can result in significant drug–drug interactions with more than thirty drugs, many taken by those with risk factors for severe COVID-19. The gene discussed is CYP3A4; the disease is COVID-19.